Industry Abstract Previews of #ACR22 The pharmaceutical companies will showcase their featured clinical trials and abstracts at #ACR22. These are their best studies for you to review and evaluate as part of your to-do list. https://t.co/8fBJmT1cXG https://t.co/r7H5sqELPo

Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd

ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN

#Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional impairment using PSOAS cohort - identified 5 clusters based on comorbidity - Depression cluster --> ↑ disease activity and fxnl impairment @RheumNow #ACR22 https://t.co/cGz4vpOGJ9

Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. Abs 1319 #ACR22 @RheumNow https://t.co/xbYW9y522I https://t.co/QQVjVXoFNf

Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP. @RheumNow https://t.co/VMkUnwWt4v https://t.co/fTRPo25GZm

PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ

In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @RheumNow https://t.co/0kyqlVphac https://t.co/HfYKCMybdL

While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW

DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt